SR
Sorrento Therapeutics, Inc.
SRNE · OTC
$0.00 +0.00% (+$0.00)
1M -42.86%
Market Cap $496.2K
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.01x
P/E N/A
P/FFO N/A
Growth
100 /100
Growing Rev. growth 25.98%
EPS growth N/A
Book val. growth N/A
Profitability
19 /100
Weak Gross margin 46.77%
FCF margin 489.37%
Net margin 911.60%
Quality
2 /100
Poor ROIC 286.80%
Asset turnover 0.13x
ROA 121.15%
Debt
50 /100
Moderate Current ratio 0.29x
Net debt/EBITDA -0.21x
Int. coverage -64.52x
Stability
50 /100
Moderate Beta 0.12x
Profitable years 0
Rev. volatility 6.83%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na SRNE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Henry H. Ji
Employees
949
Headquarters
San Diego
Nadcházející události
06 LIS
Earnings
Upcoming earnings report